- Date de réalisation : 25 Septembre 2020
- Durée du programme : 27 min
- Classification Dewey : Maladies des poumons (hypertension artérielle pulmonaire, hypertension pulmonaire, maladie obstructive respiratoire chronique, maladies respiratoires, ouvrages généraux sur les maladies des bronches et des poumons)
Dans la même collectionProf. Kingston Mills - Local T cells and their subversion in protective immunity to infection in ... Prof. Adrian Martineau - Vitamin D in the prevention and treatment of respiratory infections Dr Antoine Guillon - Flagellin-based antibacterial strategy and clinical perspectives Prof. Mike Surette - The Good and the Bad of Commensal-Pathogen Interactions in the Airways Dr Raphaël Duivenvoorden - Trained Immunity as a novel therapeutic strategy Dr Aurélie Crabbé - Host metabolites modulate bacterial susceptibility to antibiotics
Dr Mustapha Si-Tahar - Towards a metabolic anti-influenza therapy
Influenza A virus (IAV) is the etiological agent of a contagious acute respiratory disease, which is associated with high morbidity and mortality. This virus also causes a considerable socio-economic burden despite annual vaccination campaigns. To help design innovative antiviral therapies, it is essential to better understand IAV-host cells interaction. In that regard, recent studies revealed the interplay between metabolic and immune signaling pathways.
In this communication, I will present evidence that IAV alters lung tissues metabolism and I will show its functional consequence. Remarkably, we recently identified one metabolite that accumulates in the airways of IAV-infected hosts and which exhibits a potent antiviral activity, as assessed using both in vitro and in vivo approaches. I will also present the underlying inhibiting molecular mechanism that involves a specific post-translational modification process and an inhibition of IAV replication cycle. Hence, my presentation will highlight metabolites as novel components of the lung antiviral arsenal.